A gene-therapy medicine has been given commercial approval in Europe for the first time.

The treatment, Glybera, is designed to help those suffering from lipoprotein lipase deficiency -- an inherited disorder which sees patients unable to break down fats and can lead to life-threatening pancreatitis attacks.

Glybera -- the brand name for alipogene tiparvovec -- works on the genetic level by using a virus to implant working copies of the lipoprotein lipase gene into muscle cells, thus enabling production of the enzyme in those cells.

The first country to approve a gene therapy for commercial use was China in 2003 but gene therapy in Europe has, until now, been restricted to research laboratories.

Jorn Aldag, CEO of Glybera creators UniQure, said: "The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need."

The treatment is expected to come to market in 2013.

Image: Shutterstock

Here is the original post:
First commercial gene therapy approved for Europe

Recommendation and review posted by Bethany Smith

Dutch biotech company uniQure said Monday it would start selling the first human gene therapy to be approved in the West by mid-2013 and predicted an explosion of similar therapies to come.

The European Commission approved Glybera on October 25, making the drug for treating the extremely rare disorder lipoprotein lipase deficiency (LPLD) the first to be approved for sale in Europe or North America.

"We believe that after Glybera's approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade," uniQure chief executive Joern Aldag said in a statement.

Gene therapy works by modifying a patient's DNA to combat a specific disease, and has been experimented with to treat everything from blindness to depression and brain wasting diseases.

But the relatively unknown treatments have struggled to obtain regulatory approval in the West, although authorities in China approved a gene therapy for treating head and neck cancer as long ago as 2003.

Gene medicine burst on the medical scene in the late 1990s and is one of the most alluring areas of biotechnology, offering the theoretical promise of blocking or reversing inherited disease.

But this new frontier has also been hit by occasional setbacks, notably an unexpected or uncontrollable response from the immune system.

So far, successes have been few, limited to single-gene disorders -- as opposed to complex multi-gene disorders that account for the commonest diseases.

Setbacks included the tragic death of an 18-year-old US volunteer, Jesse Gelsinger, in 1999, and the development of cancer among two French children treated for "bubble baby" syndrome, a chronic lack of immune defences.

Glybera treats LPLD, an inherited disease that affects around one or two people in a million, by preventing them from metabolising certain fat particles in the blood.

More:
First gene therapy to go on sale in Europe in 2013: company

Recommendation and review posted by Bethany Smith

ScienceDaily (Nov. 5, 2012) Gene therapy can be performed safely in the human salivary gland, according to scientists at the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health.

This finding comes from the first-ever safety, or Phase I, clinical study of gene therapy in a human salivary gland. Its results, published this week in the Proceedings of the National Academy of Sciences, also show that the transferred gene, Aquaporin-1, has great potential to help head and neck cancer survivors who battle with chronic dry mouth. Aquaporin-1 encodes a protein that naturally forms pore-like water channels in the membranes of cells to help move fluid, such as occurs when salivary gland cells secrete saliva into the mouth.

These initial results clear the way for additional gene therapy studies in the salivary glands. Although sometimes overlooked, salivary glands present an ideal target for gene therapy. They are easily accessible and, once a gene is introduced, it has no obvious escape route into the bloodstream, where it can have unintended consequences.

"You cannot imagine how fulfilling it is to jot down an idea on a napkin in 1991 and then see it enter a clinical trial and help people.," said Bruce Baum, D.M.D., Ph.D., lead author on the study and recently retired NIDCR scientist who spent the last 21 years moving gene therapy in the salivary glands from the research bench to the clinic. "Can a scientist ask for anything better?"

Baum's interest in helping head and neck cancer survivors dates to the early 1980s. While attending to patients in the NIDCR's Dry Mouth Clinic, Baum encountered numerous people with head and neck cancer who had received radiation therapy to shrink their tumors. The radiation, while effective in treating cancer, had inadvertently damaged nearby salivary glands, compromising their ability to secrete saliva into the mouth.

Baum said he was thoroughly frustrated at the time because he had no effective moisture-restoring treatments to offer most patients. They had beaten cancer, but the radiation had left them with a permanent parched sensation in their mouths that diminished their quality of life and often led to chronic oral problems, such as difficulty swallowing, inflammation, infection, bad breath, and pain.

In the early 1990s, as the first gene-therapy studies entered research clinics, Baum saw an opportunity to make a difference. An initial napkin sketch of the procedure and 15 years of research later, Baum and his colleagues had assembled a compelling scientific case in animal studies that the transferred Aquaporin-1 gene, once expressed, will create new water channels in the impermeable salivary gland cells and allow water to flow through them. After rigorous reviews by NIH and the U.S. Food and Drug Administration, the Phase I protocol was launched and the first patients treated in 2008.

The scientists gave 11 head and neck cancer survivors a single-dose injection of the Aquaporin-1 gene directly into one of their two parotid salivary glands, the largest of the major salivary glands. The gene was packaged in a disabled, non-replicating adenovirus, the cause of the common cold when intact but incapable of causing a cold in this case. As is standard in gene therapy studies, the virus served as the vector, or Trojan horse, to deliver the gene into the cells lining the salivary gland.

The scientists found that five participants had increased levels of saliva secretion, as well as a renewed sense of moisture and lubrication in their mouths, within the study's first 42 days, the period covered in this report. Of the six who didn't benefit from gene therapy, none had serious side effects. The most common side effect was a transient and relatively minor immune response against the disabled adenovirus.

"It is time to evaluate a different vector to deliver the Aquaporin-1 gene, one that will cause only a minimal immune response," said Baum. "But these data will serve as stepping stones for other scientists to improve on this first attempt in the years ahead. The future for applications of gene therapy in the salivary gland is bright. "

Original post:
First gene therapy study in human salivary gland shows promise

Recommendation and review posted by Bethany Smith

cord blood center | Cord Blood Transplantation - A Life Savior Technique
http://www.cordbloodrecommendation.com Storing your babies blood is painless, and causes no harm or pain to the child or mother. Anything that can help cure illnesses and several genetic diseases is worth at least researching and contemplating because you really do never know when you may need it. This type of stem cells is found in baby cord blood and adult bone marrow. Umbilical blood banking provides the ideal stem cell match should a patient require stem cell therapy in their lifetime. Hence opt for cord blood storage banks that can show proof of successful transplants from the cord blood units they have stored in order to avoid rude shocks. If you are an expecting mother, you can look for a bank or designated donation hospital in your community. In cases of leukemia, stem cells can be used to generate healthy blood and fight off the cancer cells in the body. Furthermore, collecting umbilical cord blood has no controversy since the process does not cause the destruction on the embryos and fetus. ""Leukemia is a type of cancer that begins from those tissues in the body that form blood. Ultra-modern cord blood banking technologies induce multiplication of cord blood stem cells by ex vivo expansion. Last but not the least, if you do not want to store the blood for your personal usage in any of these banks you can also donate it to the Medical Institutes for research purposes. Stem cells, researchers discovered, could cure many diseases such as leukemia and help others such as ...From:Implantes DentalesViews:0 0ratingsTime:01:31More inTravel Events

Original post:
cord blood center | Cord Blood Transplantation - A Life Savior Technique - Video

Recommendation and review posted by simmons

stem cells | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com You never know when you might need this blood and it might give your child a new life. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Most of the private and public banks were founded during the 1990s. In a laboratory test, cord blood stem cells were transplanted into rodents with controlled strokes. With the success from transfusions creating immune system stability, and creating new oxygen baring cells for many diseases, researchers are hoping that more diseases can not only be treated effectively, but possibly stopped in their tracks altogether. In cancer patients, such as those with leukemia, the introduction of HSC #39;s into the body may rapidly produce healthy cells that can replace destroyed cells from chemotherapy and/or hopefully prevent infections that often create complications or even death, during the treatment process. If you pass all the tests you will be free to donate your baby #39;s blood. Although some will allow you to prepay during your pregnancy so as to not have to pay the amount all in one lump sum, but in general all initial fees must be paid well in advance of delivery in order to utilize the private storage services. According to the most current data, the prospect of needing a stem cell transplant in any individuals Life is 1 in 217! So you can imagine that the likelihood of your baby, or one of your family members needing this kind of help is ...From:kristinagraddyViews:0 0ratingsTime:01:31More inTravel Events

More here:
stem cells | Cryo-Cell - Cord Blood Banking Information For Parents - Video

Recommendation and review posted by simmons

FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy?
youtu.be People ask us if stem cell therapy can CAUSE cancer, and they are wise to be wary, but stem cell therapy has been proving effective AGAINST cancer, and has not cause any known cases of cancer to-date. For more personalized information, visit StemCell-Asia.info now.From:Karridine1Views:1 0ratingsTime:01:06More inPeople Blogs

View original post here:
FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy? - Video

Recommendation and review posted by simmons

FAQ-11 of 19: For Stem Cell Therapy, Why Thailand #39;s Licensed Stem Cell Treatments?
youtu.be You may wonder why coming to Thailand is a better investment of time, energy and resources, so here are some answers. For more personalized information as to how your condition might respond to stem cell therapy, go to the Apply Now page and send in copies of your medical records with an Application for Consideration. StemCell-Asia.infoFrom:Karridine1Views:0 0ratingsTime:01:16More inPeople Blogs

See the original post:
FAQ-11 of 19: For Stem Cell Therapy, Why Thailand's Licensed Stem Cell Treatments? - Video

Recommendation and review posted by simmons

Arthritis
Call: 305-695-7777 For More Information Arthritis has been something historically very hard to cure, but we maybe one step closer to a cure by using stem cell therapies instead of steroids and other types of medications. At Miami Beach Foot and Ankle Surgery we have been utilizing PRP (platelet rich plasma) therapy as well as amniotic stem cell therapy, which is important in the world of arthritis.From:MiamiFootSurgeryViews:11 0ratingsTime:01:12More inHowto Style

Here is the original post:
Arthritis - Video

Recommendation and review posted by simmons

Muscular Dystrophy Before and After Stem Cell Therapy
He took stem cell therapy at NeuroGen. Previously when he was climbing stairs, he was widening steps and climbing stairs. And he was taking more time, now he is taking less time. Climb stairs straight. Previously during sit to stand, he was taking support of hands and was coming up, but now he is not taking support. Previously when he was sitting on floor, he was facing in coming up and facing problem in walking few steps. But after stem cell therapy he can walk normally now. Now changes are seen. Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:0 0ratingsTime:00:37More inScience Technology

Continue reading here:
Muscular Dystrophy Before and After Stem Cell Therapy - Video

Recommendation and review posted by simmons

The Patients of Angeles Health International
What our patients have to say about their experiences at Angeles Health International. All patients were treated for different conditions, in separate departments throughout our facilities. Angeles Health International offer cutting edge care, procedures and treatment in the following areas: Weight Loss Surgery - http://www.weightlossmex.com Stem Cell Therapy - http://www.stemcellmx.com Multiple Sclerosis Treatment - http://www.ccsvi.mx Effective Chemotherapy-free Cancer Treatment - http://www.cancertreatmentmx.com Visit the Angeles Health International website here: http://www.angeleshealth.com There are a team of healthcare professionals waiting to hear from you. Contact Angeles Health International toll free on: 1.866.668.9263From:AngelesHealthViews:0 0ratingsTime:03:06More inScience Technology

View original post here:
The Patients of Angeles Health International - Video

Recommendation and review posted by simmons

Stem Cell Malaysia | Stem Cell Therapy
stemcellmalaysia.com Stem Cell Malaysia shares with you actual user experience on stem cell therapy. Stem Cell Malaysia also provides useful information on stem cells, stem cell therapy, stem cell research and stem cell newsFrom:stemcells2012Views:0 0ratingsTime:03:17More inHowto Style

Follow this link:
Stem Cell Malaysia | Stem Cell Therapy - Video

Recommendation and review posted by simmons

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: NHLBI Communications NHLBI_news@nhlbi.nih.gov 301-496-7510 NIH/National Heart, Lung and Blood Institute

Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

The findings will be presented Tuesday, Nov. 6, at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts."

"With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function," added fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute, who will present the results at the meeting. "For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery."

Skarlatos noted that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

Between July 2008 and February 2011, TIME researchers enrolled 120 volunteers (average age 57, 87.5 percent male) who suffered from moderate to severe impairment in their left ventricles the part of the heart that pumps oxygen-rich blood to the body and had undergone stenting procedures following heart attacks. Those selected for the trial were assigned randomly to one of four groups: day three after heart attack stem cell injection, day three after heart attack placebo injection, day seven after heart attack stem cell treatment, or day seven after heart attack placebo treatment. The researchers developed a method of processing and purifying the stem cells to ensure that participants in the stem cell groups received a uniform dose of 150 million cells about 8 hours after the cells were harvested from their bone marrow. This ensured that results would not be skewed by differences in the quantity or quality of stem cells administered.

Researchers assessed heart improvement six months after stem cell therapy by measuring the percentage of blood that was pumped out of the left ventricle during each contraction (known as the left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six-month follow-up in either the day three or the day seven stem cell groups compared with placebo groups or with each other. Every group showed about a three percent improvement in LVEF.

View original post here:
Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack

Recommendation and review posted by simmons

Personalized Medicine Tshishiku Chiang Pickerell Ratajczak Pathipati
From:ES139239Views:0 0ratingsTime:04:54More inFilm Animation

Read the original here:
Personalized Medicine Tshishiku Chiang Pickerell Ratajczak Pathipati - Video

Recommendation and review posted by sam

Machine Learning for Industry with Microsoft Research Lead Scientist
Machine learning is a powerful industry tool with applications from ad prediction to personalized medicine. John Langford is a machine learning research scientist at Microsoft Research New York, the principal developer of Vowpal Wabbit, and the program co-chair for the 2012 International Conference on Machine Learning. To see more videos from the 2012 Siebel Scholars Conference including discussions on class warfare and inequality David Brooks, New York Times; William Galston, Brookings Institute; Niall Ferguson, Harvard University and Hoover Institution; Lewis Lapham, Lapham #39;s Quarterly; Charles Murray, American Enterprise Institute; Ralph Nader; Robert Reich, former Secretary of Labor; Condoleezza Rice, former Secretary of State; and Thomas M. Siebel, chairman, Siebel Scholars Foundation, visit http://www.youtube.com Learn more about Siebel Scholars at http://www.siebelscholars.comFrom:SiebelScholarsViews:1 0ratingsTime:21:32More inPeople Blogs

Read more:
Machine Learning for Industry with Microsoft Research Lead Scientist - Video

Recommendation and review posted by sam

Spinal Cord Injury c6 Level Before and After Stem Cell Treatment
Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:2 0ratingsTime:01:15More inScience Technology

Read more:
Spinal Cord Injury c6 Level Before and After Stem Cell Treatment - Video

Recommendation and review posted by sam

Spinal Cord Injury D4 Level Before and After Stem Cell Treatment
Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:0 0ratingsTime:01:29More inScience Technology

Originally posted here:
Spinal Cord Injury D4 Level Before and After Stem Cell Treatment - Video

Recommendation and review posted by sam

Holiday Message from Benton and Garret Truttman
Benton and Garret Trottman are thankful for their grandmother, Joyce. This fall, Joyce came to Mary Free Bed Rehabilitation Hospital to recover from a spinal cord injury. To help their grandmother, the 11-year-old twins decided that instead of asking for presents for their birthday, they would ask for donations to benefit the Mary Free Bed Spinal Cord Program. Benton and Garret also asked the children attending their party to make get-well cards for Mary Free Bed patients.From:MaryFreeBedViews:7 0ratingsTime:00:45More inEducation

Visit link:
Holiday Message from Benton and Garret Truttman - Video

Recommendation and review posted by sam

PRESS RELEASE 3 November 2012

Auckland Mum to run/walk 500km with O Sleep in aid of the CatWalk Spinal Cord Injury Trust and Auckland Spinal Trust

The Blue Light 500kms, O sleep

On Thursday 22 November Kim Allan will begin an attempt to run/walk for 500km continuously without sleep around Auckland Domain in aid of the CatWalk Spinal Cord Injury (SCI) Trust and the Auckland Spinal Trust. The challenge has been supported by Blue Light and is known as the Blue Light 500km, 0 Sleep. The ultra-distance attempt is expected to take Kim four days during which time she will not be able to sleep or rest for any significant length of time. Kim points out, This will be a huge challenge, not only physically but mentally and there are days I simply cant get my head around being awake for that length of time. But in the words of Nelson Mandela, It always seems impossible until it is done says Kim.

The Charity Blue Light is supporting Kim in her attempt and has provided initial sponsorship hence the challenge has been named Blue Light 500kms, O Sleep. We were so inspired by Kims extreme commitment to help others and also her dogged determination to attempt something that seems almost impossible said Rod Bell, Blue Light CEO. With all our youth programs and life skills camps we are teaching young people to believe in their goals and Kims attempt exemplifies this very belief.

Kim first decided to take up ultra-distance events as a way to encourage her children to stay committed and work through hard times. Her son now laughingly points out Ok Mum, youve made your point. Having competed in several ultra-events, including the OxfamTrail Walker and the NZ 24 hour race, Kim decided to attempt something she thought might provide the ultimate challenge. She admits there is no guarantee that she can actually do it and therefore the challenge is huge.

Due to the fact Kim will not be able to sleep during her attempt she will need encouragement to keep going and the public are invited to come to the Domain anytime from Thurs 22 through to Sunday 25 November to cheer her on. On Thursday Kim will be joined by a group of young people taking part in the first

Blue Light International Youth Leadership Program. These young people will join Kim for several laps of the Domain. Having never been attempted before Kim hopes to beat the record set by Pam Reed, the American Ultra runner, who completed 486km over 80 hours. Kim points out that the time within which she completes the event is not important its the distance she is aiming to cover, however, the sooner she gets it done the quicker she can get to sleep.

To support Kims fundraising efforts for Spinal Injury please make a donation at http://www.fundraiseonline.co.nz/KimAllen and you can follow Kim via Facebook on http://www.facebook.com/bluelight500kmOsleep

New Zealand Blue Light

Read more here:
Auckland Mum to run/walk 500km without sleep for charity

Recommendation and review posted by sam

London, Nov.5 (ANI): Living in a care home has a devastating impact on the lives of people paralysed by spinal cord injury, according to research by Loughborough University academic Dr Brett Smith.

Dr Smith, from the University's School of Sport, Exercise and Health Sciences, found that lives are put at risk by unsuitable care and facilities, and by suicidal feelings due to poor quality of life. Dr Smith was commissioned by the spinal injury charity Aspire to examine the effect of the common practice of forcing people with spinal cord injury to live in care homes for the elderly.

An expert in disability, health and physical activity, Dr Smith said: "The findings of this study are hugely important. It is the first time that anyone has looked into the damage done by the common practice of housing spinal injured people in care homes. "This research has really opened my eyes and I hope it will start to make people sit up and take notice. The lack of accessible housing provision is essentially ruining lives."

Research findings detail the risks to physical health such as pressure sores, infections and even broken bones, whilst the psychological risks include chronic depression, self harm and suicidal thoughts. The consequences of housing a spinal injured person in a care home are so destructive that it is unacceptable for public policy to continue to allow this as an option.

Every eight hours someone is paralyzed by a spinal cord injury and told that they will never walk again. Twenty per cent of these people will be discharged from hospital into a care home, regardless of their age, because they do not have housing in the community that meets their new needs. The study by Dr Smith and his team involved extensive interviews with 20 spinal injured people who are living or who have lived in care homes. Research findings clearly show that care homes are completely inappropriate places to house spinal injured people, and yet some people remain in care homes for periods of up to three years or more.

People in this situation experience a diminished quality of life due to their lack of independence, damage to relationships, isolation and boredom. Furthermore, lack of specialist knowledge among care home staff and inadequate facilities mean that people's physical health needs are often not met, resulting in further injury, pain and illness.

A research participant said: "Staff tried transferring me with a slideboard, but they didn't do it properly. Bang. I ended on the floor, my arm broken. They mean well often, but they don't know how to look after people with a spinal injury. And this is just the half of it. I've even been given wrong medication. I could have died."

Another participant said: "All my independence has gone since living in here. This place has taken it away. My quality of life as a result has suffered immensely. I've no quality of life now, and feel like I'm not even a human being anymore."

Brian Carlin, Chief Executive of Aspire, said: "All too often, people with spinal cord injury find themselves discharged to somewhere totally unsuitable and, as this study confirms, care homes are often the very worst option for someone recovering from a traumatic spinal injury.

The Government is aiming to increase employment rates among disabled people, and most disabled people would like to be in work.However, research participants reported that care home staff are regularly not able to help them out of bed until midday, and in some cases people were left in bed all day if the home was short staffed. If the Government continues to allow people with spinal cord injury to be housed in care homes, they are removing their ability to gain employment.

Read more:
Loughborough Varsity research says lives of spinal cord injury victims at risk in care homes

Recommendation and review posted by sam

454: A Documentary About Stem Cell Research
In 2004 Alex Goldberg, then a 20 year old local filmmaker began a documentary on stem cell research at the University of Washington. On June 16 2011, he died before the film was finished. This film highlights the need for this research to continue in order to save thousands of lives. In this unsettling political climate, the film resonates. It was made during the Bush era when stem cell lines were limited, thus stunting the research and in turn a cure for so many diseases. Many thanks to Dr Charles Murry and his staff for their tireless efforts to create therapies in regenerative medicine. Dr Murry may be reached through the University of Washington research labs. If you would like to make donations to help fund this research and the researchers who work without appropriate compensation please click the following link: depts.washington.eduFrom:Leta GoldbergViews:67 2ratingsTime:15:03More inEducation

See the original post here:
454: A Documentary About Stem Cell Research - Video

Recommendation and review posted by sam

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT, OTCBB: ACTC or the Company), a leader in the field of regenerative medicine announced today that it will release its third quarter 2012 financial results on Thursday, November 8th after the market closes. The Company will hold a conference call at 4:30 p.m. EST that day during which it will discuss its results and provide a corporate update.

Interested parties may dial (888) 264-3177 or 706-902-4345 using reference conference ID number 90962762. The call will be available live and for replay by webcast at: http://us.meeting-stream.com/advancedcelltechnology110812 .

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visitwww.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

See the rest here:
Advanced Cell Technology to Announce Third Quarter Financial Results on Thursday, November 8th

Recommendation and review posted by sam

Denver, CO (PRWEB) November 05, 2012

The American Institute of Architects has recognized Curtis Fentress as the 2012 Colorado Architect of the year and acknowledged two of Fentress Architects most innovative designs. The Sanford Consortium for Regenerative Medicine has won both the 2012 AIA Colorado Honor Award for Built Architecture and the 2012 AIA Denver Merit Award for Built Architecture. Mineta-San Jose International Airport Terminal B has won the 2012 AIA Colorado Merit Award for Built Architecture.

Were deeply honored and humbled by these awards, said Curtis Fentress. Its a testament to the artistry and dedication of our teams. Theyre the ones who turned these ideas into reality.

Curtis Fentress, FAIA, RIBA

Awarded: 2012 AIA Colorado Architect of the Year

Curtis Fentress career illustrates how design excellence can elevate and transform the publics understanding and experience of architecture. Fentress body of work is replete with projects uniquely appropriate to their communities architecture with humanism at its heart, designed to stand the test of time. For over three decades, Curtis Fentress and his team have focused on designing enduring public architecture, applying the firms expertise and resources to elevate the human experience in public buildings.

His buildings are keenly aligned with their environmental context, culture and intent. His design philosophy developed through work on Colorado projects such as 1999 Broadway, with its blend of modernist elements that never the less relate to the historic nature of the Holy Ghost Church with which it shares space; Denver International Airport, which quickly became a regional icon and one of the most recognized airports in the world; and vital life-safety work on the beloved Colorado State Capitol. In 2009, Fentress was the first and only architect to be inducted into the Visit Denver Tourism Hall of Fame, honoring the impact his projects have had on the physical, economic and civic landscapes of the region.

Under his direction, Fentress Architects has won more than 400 awards and accolades, including 80 awards from his peers in the AIA, and has won 34 national and international competitions. A Fellow of the AIA, Fentress and his firm have designed $27 billion of architectural projects worldwide, visited by over 350 million people annually. He serves widely as a lecturer at colleges and universities throughout the United States and abroad.

Sanford Consortium for Regenerative Medicine

Awarded: 2012 AIA Colorado Honor Award for Built Architecture; 2012 AIA Denver Merit Award for Built Architecture

Read the original:
Fentress Architects Take Home Three Prestigious Design Awards and Colorado Architect of the Year

Recommendation and review posted by sam

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - Nov 5, 2012) - Regenerative medicine company Avita Medical Ltd. ( ASX : AVH ) ( OTCQX : AVMXY ) today announced that it will be presenting at the upcoming SoCalBio Investor Conference & Exhibition. The event will take place on November 7, 2012 at the Omni Hotel in Los Angeles, California.

The Company will be presenting in the Wound Healing & Regenerative Medicine Group.

"We are pleased to be presenting at this quality bioscience industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell SprayOn Skin is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among the US investment community as we approach FDA submission."

This is a one-day conference organized annually by the Southern California Biomedical Council (SoCalBio) to showcase the strength and future of the bioscience industry in Los Angeles/Orange County and neighboring communities. For more information on the conference: http://www.socalbio.org/SocalBio_2012/home_2012.htm

ABOUT AVITA MEDICAL LTD. Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell Spray-On Skin, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Original post:
Avita Medical to Present at SoCalBio Investor Conference & Exhibition

Recommendation and review posted by sam

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: Katie Pence katie.pence@uc.edu 513-558-4561 University of Cincinnati Academic Health Center

CINCINNATIHoxworth Blood Center, the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center will host the Midwest Symposium on New Concepts For Tissue-Specific Regenerative Medicine, Nov 17-18, 2012, in Rieveschl Auditorium of the Vontz Center for Molecular Studies.

The symposium, also being co-sponsored and co-funded by UC's Center for Clinical and Translational Science and Training (CCTST), will focus on research and collaboration regarding regenerative medicinethe process of regenerating human cells, tissues or organs to restore or establish normal function.

The field holds the promise of repairing damaged tissues and organs in the body by stimulating the body's own repair mechanisms or by growing replacement tissues in labs.

Jose Cancelas, MD, PhD, professor of pediatrics at the UC College of Medicine and director of the research division at Hoxworth Blood Center, is a co-organizer of the symposium and says regenerative medicine expertise is very strong in the region.

"The purpose of the symposium will be to create a forum where investigators and their groups can meet and share ideas and data," he says. "In addition, it will serve as an excellent platform for regional scientific interactions for investigators, postdocs and students that have interest in regenerative medicine and stem cell biology. Hopefully, this meeting will spark collaborations locally and regionally."

Specifically, the meeting will focus on research using stem cells in the body, or those manipulated in a petri dish, to study disease, generate therapeutic tissues and create genetic therapies.

Keynote speakers will deliver addresses followed by short oral presentations with extended discussions to allow interaction among attendees.

"Research presentations will span from how scientists are looking at the use of stem cells to assist with gastrointestinal, pancreas, lung, corneal, skeletal muscle, vascular and cardiac regeneration to genetic therapies and how this research could and is translating to treatment," Cancelas says. "There's a wealth of scientific and clinical stem cell work being done right here in Cincinnati.

View original post here:
Midwest regenerative medicine symposium to be held in Cincinnati

Recommendation and review posted by sam

cryocell | Umbilical Cord Stem Cells - Hope For a Better Tomorrow With Cord Blood Banking
http://www.cordbloodrecommendation.com However, the fees from bank to bank are pretty similar across the board. It is ready-to-use, as it is stored frozen after collecting and testing it. However, this blood can be used for non-family members and is being used to treat diseases and save lives. Secondly they regenerate cells to treat heart and circulatory diseases. Swarms of people are visiting the hospital to know more about preservation and how it is going to be beneficial for them in times of medical emergencies. The latter comes under much scrutiny and debate. However, looking at the benefit your child or may be his siblings may get 20 years down the line, you can definitely think of it as an insurance premium. 4. She was in the advanced stages of Parkinson and was looking for treatment options. How Can I Save My Baby #39;s Cord Blood?You can save it by storing it in a private cord blood bank, but if you do not save it, it will be discarded after birth. The proportion of unsuccessful searches is even greater among patients not of Northern European descent. Compared to bone marrow stem cells, cord blood stem cells are easier to harvest because they are easily obtainable from placenta after delivery and so do not involve a surgical procedure. The transplants are used to treat diseases as well as immune system problems. Most, if not all, of the major cord blood banking companies allow you to create a gift registry - similar to the popular registries at baby retailers - so that ...From:luisantafeViews:1 0ratingsTime:01:31More inTravel Events

More here:
cryocell | Umbilical Cord Stem Cells - Hope For a Better Tomorrow With Cord Blood Banking - Video

Recommendation and review posted by Bethany Smith